Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 47Terminated 9Unknown 3Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 22NETWORK 3INDUSTRY 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Prostate Cancer 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Leuprolide × Clear all
NCT05827081 2026-05-14

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Astellas Pharma Inc

Phase 2 Recruiting
900 enrolled
Genitourinary

Prostatic Neoplasms

NCT06490328 2024-07-08

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Dongkook Pharmaceutical Co., Ltd.

Phase 3 Recruiting
154 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡